Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1025-1036 , December 2007

Localized scleroderma and systemic sclerosis: Is there a connection?

  • Rajnish A. Gupta, MD, PhD (Fellow)
    • ,
  • David Fiorentino, MD, PhD (Assistant Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Dermatology, Stanford University Medical Center, 900 Blake Wilbur Drive, Stanford, CA 94305, USA. Tel.: +1 650 723 9913; Fax: +1 650 723 7796.

References 

  1. Mayes MD. Epidemiology of systemic sclerosis and related diseases. Current Opinion in Rheumatology. 1997;9(6):557–561
  2. Valentini G, Black C. Systemic sclerosis. Best Practice and Research. Clinical Rheumatology. 2002;16(5):807–816
  3. Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis and Rheumatism. 1997;40(3):441–445
  4. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. The Journal of Rheumatology. 1997;24(1):73–80
  5. Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis and Rheumatism. 2001;44(6):1359–1362
  6. Feghali-Bostwick C, Medsger TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis and Rheumatism. 2003;48(7):1956–1963
  7. Sato H, Lagan AL, Alexopoulou C, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis and Rheumatism. 2004;50(2):558–564
  8. Assassi S, Tan FK. Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Current Opinion in Rheumatology. 2005;17(6):761–767
  9. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 1998;351(9102):559–562
  10. Iranzo P, Lopez I, Palou J, et al. Morphoea in three siblings. Journal of the European Academy of Dermatology and Venereology. 2001;15(1):46–47
  11. Patrizi A, Marzaduri S, Marini R. A familial case of scleroderma en coup de sabre. Acta Dermato-Venereologica. 2000;80(3):237
  12. Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clinical and Experimental Rheumatology. 1999;17(6):718–720
  13. Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Natural Medicines. 2000;6(10):1183–1186
  14. Nietert PJ, Silver RM. Systemic sclerosis: environmental and occupational risk factors. Current Opinion in Rheumatology. 2000;12(6):520–526
  15. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. British Journal of Dermatology. 2000;142(4):636–644
  16. Tuffanelli DL. Localized scleroderma. Seminars in Cutaneous Medicine and Surgery. 1998;17(1):27–33
  17. Chung L, Lin J, Furst DE, et al. Systemic and localized scleroderma. Clinics in Dermatology. 2006;24(5):374–392
  18. Zulian F. Systemic manifestations in localized scleroderma. Current Rheumatology Reports. 2004;6(6):417–424
  19. Dehen L, Roujeau JC, Cosnes A, et al. Internal involvement in localized scleroderma. Medicine (Baltimore). 1994;73(5):241–245
  20. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis and Rheumatism. 2005;52(9):2873–2881
  21. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. The Journal of Clinical Investigation. 2007;117(3):557–567
  22. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. The Journal of Experimental Medicine. 1979;149(6):1326–1335
  23. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Current Opinion in Rheumatology. 2004;16(6):718–722
  24. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. The Journal of Clinical Investigation. 1996;98(3):785–792
  25. Helmbold P, Fiedler E, Fischer M, et al. Hyperplasia of dermal microvascular pericytes in scleroderma. Journal of Cutaneous Pathology. 2004;31(6):431–440
  26. Artlett CM. Immunology of systemic sclerosis. Frontiers in Bioscience. 2005;10:1707–1719
  27. Ihn H, Yazawa N, Kubo M, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. The Journal of Rheumatology. 2000;27(3):698–702
  28. Hu PQ, Fertig N, Medsger TA, et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis and Rheumatism. 2003;48(5):1363–1373
  29. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Current Opinion in Rheumatology. 2004;16(6):723–732
  30. Falanga V, Medsger TA, Reichlin M, et al. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Annals of Internal Medicine. 1986;104(6):849–857
  31. Sato S, Fujimoto M, Ihn H, et al. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. Journal of the American Academy of Dermatology. 1994;31(4):567–571
  32. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford). 2005;44(3):274–279
  33. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. The New England Journal of Medicine. 2006;354(25):2667–2676
  34. Falanga V, Medsger TA, Reichlin M. High titers of antibodies to single-stranded DNA in linear scleroderma. Archives of Dermatology. 1985;121(3):345–347
  35. Hayakawa I, Hasegawa M, Takehara K, et al. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis and Rheumatism. 2004;50(1):227–232
  36. Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis and Rheumatism. 1993;36(8):1137–1141
  37. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Current Opinion in Rheumatology. 2004;16(6):739–745
  38. Ihn H, Yamane K, Kubo M, et al. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis and Rheumatism. 2001;44(2):474–480
  39. Kubo M, Ihn H, Yamane K, et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis and Rheumatism. 2001;44(3):731–734
  40. Asano Y, Ihn H, Jinnin M, et al. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. The Journal of Investigative Dermatology. 2006;126(8):1761–1769
  41. Zhou L, Askew D, Wu C, et al. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. The Journal of Investigative Dermatology. 2007;127(2):281–292
  42. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(21):12319–12324
  43. Tan FK, Hildebrand BA, Lester MS, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis and Rheumatism. 2005;52(3):865–876

PII: S1521-6942(07)00106-4

doi: 10.1016/j.berh.2007.09.003

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1025-1036 , December 2007

Article Tools